Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Eloxx Pharmaceuticals, Inc. (ELOX)

Eloxx Pharmaceuticals effects 1-for-11 reverse split and adds two directors

Neutral Impact 4 of 5 shareholder Written later

Eloxx Pharmaceuticals completed a 1-for-11 reverse stock split of its common stock, effective 5:00 p.m. Eastern Time on May 29, 2026, and reduced authorized common shares from 500,000,000 to 100,000,000. The company also appointed Stephen W. Webster and Nina Kjellson to its board, filling vacancies and reducing the board from six to five directors.

Key points

  • Every 11 shares of common stock combined into one share; trading on a split-adjusted basis expected on the OTC Pink Market on June 1, 2026
  • Authorized common shares reduced from 500,000,000 to 100,000,000
  • Stephen W. Webster and Nina Kjellson appointed to the board on May 27, 2026; each received an option grant for up to 13,587 shares
  • Prefunded warrant exercises of 2,500,000 shares occurred on April 27, 2026, and an exchange of those shares for prefunded warrants on May 27, 2026

The filing

CompanyEloxx Pharmaceuticals, Inc. (ELOX)
Form8-K, current report
Filed with the SECJun 1, 2026, 7:00 AM ET
Accession number0001193125-26-249692

Items reported: 3.02 Unregistered Equity Sale3.03 Change to Shareholder Rights5.02 Director / Officer Change5.03 Bylaw / Charter Amendment

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.